Clinical Trial Update: Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated local ablative therapy for oligoprogressive, EGFR-mutated non-small cell lung cancer after treatment with osimertinib.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma
• Non-small Cell Lung Cancer

Drugs mentioned

• Osimertinib (osimertinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Lung Adenocarcinoma, Lung Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2023-07-25